E5103 Treatment Form - Step 2 (Arm D ONLY) NCT00433511 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Source Form: NCI FormBuilder:

  1. 8/26/12 8/26/12 -
  2. 1/8/15 1/8/15 - Martin Dugas
  3. 6/3/15 6/3/15 -
Uploaded on:

June 3, 2015

To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

E5103 Treatment Form - Step 2 (Arm D ONLY) NCT00433511

INSTRUCTIONS: Complete this form at the end of each cycle (1 cycle =3 weeks). Submit original to the ECOG Coordinating Center. Keep a copy for your files. Refer to forms packet for submission schedule

Header module
Reporting Period
On Treatment Report Period (ARM D ONLY)
Therapy Administered
Dose modification
Dose Modification Reason (* If a dose modification reason represents a qualifying Grade CTCAE, report the event on the E5103 Adverse Event Form.)
Adverse Event (Instruction: If Bevacizumab dose was modified for adverse event, mark an 'X' for all that apply:)
Non-protocol Therapy
Was any non-protocol cancer therapy given during protocol treatment (not previously reported - * Bisphosphonate Therapy will NOT be considered non-protocol therapy.)

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial